Lesson plan
MVA85A
MVA85A (modified vaccinia Ankara 85A) was a candidate vaccine against tuberculosis developed by researchers led by Professor Helen McShane at Oxford University. It is a viral vector vaccine and consists of an MVA virus engineered to express the 85A antigen once it infects a host cell. 85A is a cell-wall protein of the tuberculosis bacillus. This vaccine was believed to produce higher levels of long-lasting cellular immunity when used together with the older TB vaccine BCG. Phase I clinical trials were completed in 2008 and then phase II clinical trials took place in South Africa. A number of efficacy trials ran in parallel from 2009 to 2019. Results released in February 2013 were described as "disappointing", showing only a statistically insignificant prevention rate in infants. A summary of animal studies published in 2015 cast doubt on the efficacy of the vaccine. In 2018, a BMJ investigation raised concerns about the ethics of an efficacy trial in South African infants, particularly because of results from earlier animal trials such as a study with macaques at Porton Down. One response argued that 14 prior human trials showed a safety signal, that regulators were aware of the primate trial and decided to continue, and that three subsequent investigations found no evidence of wrong-doing. Another response by Ian Orme questioned the critique of animal models.…
Article summary
MVA85A (modified vaccinia Ankara 85A) was a candidate vaccine against tuberculosis developed by researchers led by Professor Helen McShane at Oxford University. It is a viral vector vaccine and consists of an MVA virus engineered to express the 85A antigen once it infects a host cell. 85A is a cell-wall protein of the tuberculosis bacillus. This vaccine was believed to produce higher levels of long-lasting cellular immunity when used together with the older TB vaccine BCG. Phase I clinical trials were completed in 2008 and then phase II clinical trials took place in South Africa. A number of efficacy trials ran in parallel from 2009 to 2019. Results released in February 2013 were described as "disappointing", showing only a statistically insignificant prevention rate in infants. A summary of animal studies published in 2015 cast doubt on the efficacy of the vaccine. In 2018, a BMJ investigation raised concerns about the ethics of an efficacy trial in South African infants, particularly because of results from earlier animal trials such as a study with macaques at Porton Down. One response argued that 14 prior human trials showed a safety signal, that regulators were aware of the primate trial and decided to continue, and that three subsequent investigations found no evidence of wrong-doing. Another response by Ian Orme questioned the critique of animal models.…
Key claims
- publication date: 2015 — source: Wikipedia, revision 1336874482, retrieved 2026-10-20 · confidence 0.95
- release date: 2013 — source: Wikipedia, revision 1336874482, retrieved 2026-10-20 · confidence 0.95
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- The record states that the publication date is "2015". What evidence would count against this claim?
- The record states that the release date is "2013". What evidence would count against this claim?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
- Wikipedia, “MVA85A”, revision 1336874482, retrieved 2026-10-20 https://en.wikipedia.org/w/index.php?oldid=1336874482
Key claims and bibliography are generated from the same tracked claims and sources as the article page.